• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在胰岛素依赖型糖尿病中,每日快速的血糖变化可能会影响抗凝血酶III的生物活性,但不会影响其血浆浓度。不稳定的非酶糖基化可能起到一定作用。

Daily rapid blood glucose variations may condition antithrombin III biologic activity but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic glycation.

作者信息

Ceriello A, Giugliano D, Quatraro A, Stante A, Consoli G, Dello Russo P, D'Onofrio F

出版信息

Diabete Metab. 1987 Feb;13(1):16-9.

PMID:3569629
Abstract

The effect of rapid daily variation of glycemia and labile HbA1 on both antithrombin III (ATIII) activity and plasma concentration in ten insulin dependent diabetics has been evaluated. The variations of both plasma glucose and labile HbA1 were inversely correlated to the alterations of ATIII activity (r = -0.71 and r = -0.73, respectively, p less than 0.001), while no change in ATIII plasma concentration was present. These data suggest a direct role of glucose in determining rapid alteration of ATIII biologic activity, in vivo, in diabetes, probably mediated by labile non-enzymatic glycation.

摘要

已评估了10名胰岛素依赖型糖尿病患者中血糖的每日快速变化及不稳定糖化血红蛋白(HbA1)对抗凝血酶III(ATIII)活性和血浆浓度的影响。血浆葡萄糖和不稳定HbA1的变化与ATIII活性的改变呈负相关(r分别为-0.71和-0.73,p<0.001),而ATIII血浆浓度无变化。这些数据表明,在糖尿病患者体内,葡萄糖在决定ATIII生物活性的快速改变中起直接作用,这可能由不稳定的非酶糖基化介导。

相似文献

1
Daily rapid blood glucose variations may condition antithrombin III biologic activity but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic glycation.在胰岛素依赖型糖尿病中,每日快速的血糖变化可能会影响抗凝血酶III的生物活性,但不会影响其血浆浓度。不稳定的非酶糖基化可能起到一定作用。
Diabete Metab. 1987 Feb;13(1):16-9.
2
Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics.
Haemostasis. 1986;16(6):458-64. doi: 10.1159/000215325.
3
Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation--a preliminary report.糖尿病患者抗凝血酶III活性降低可能与非酶糖基化有关——初步报告。
Thromb Haemost. 1983 Oct 31;50(3):633-4.
4
Metabolic control may alter antithrombin III activity but not its plasma concentration in diabetes: a possible role for nonenzymatic glycosylation.代谢控制可能改变抗凝血酶III的活性,但不会改变糖尿病患者血浆中其浓度:非酶糖基化可能起作用。
Diabetes Care. 1986 Jan-Feb;9(1):32-5. doi: 10.2337/diacare.9.1.32.
5
Antithrombin III activity and concentration in diabetes mellitus.
Thromb Haemost. 1985 Aug 30;54(2):415-7.
6
Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects.在健康正常受试者中,诱导性高血糖会改变抗凝血酶III的活性,但不会改变其血浆浓度。
Diabetes. 1987 Mar;36(3):320-3. doi: 10.2337/diab.36.3.320.
7
Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations.低分子量肝素可从高血糖诱导的改变中恢复抗凝血酶III活性。
Diabete Metab. 1990 Mar-Apr;16(2):86-92.
8
Increased alpha 2-macroglobulin in diabetes: a hyperglycemia related phenomenon associated with reduced antithrombin III activity.
Acta Diabetol Lat. 1989 Apr-Jun;26(2):147-54. doi: 10.1007/BF02581366.
9
More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity.在1型糖尿病患者中,加用格列本脲至胰岛素治疗后,血糖的日间控制更加均匀,每日胰岛素剂量减少:胰岛素敏感性增强的作用。
Diabet Med. 1995 Oct;12(10):880-4. doi: 10.1111/j.1464-5491.1995.tb00390.x.
10
Antithrombin III and fibrinogen degradation product (fragment E) in diabetic nephropathy.糖尿病肾病中的抗凝血酶III和纤维蛋白原降解产物(E片段)
J Clin Pathol. 1982 Jun;35(6):661-6. doi: 10.1136/jcp.35.6.661.

引用本文的文献

1
Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.糖尿病并发症发生过程中的糖基化、氧化和脂氧化:一种羰基应激假说。
Diabetes Rev (Alex). 1997;5(4):365-391.
2
Molecular basis for a link between complement and the vascular complications of diabetes.补体与糖尿病血管并发症之间联系的分子基础。
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5450-5. doi: 10.1073/pnas.97.10.5450.
3
Physiological inhibitors of blood coagulation and prothrombin fragment F 1 + 2 in type 2 diabetic patients with normoalbuminuria and incipient nephropathy.
正常白蛋白尿和早期肾病的2型糖尿病患者的生理性凝血抑制剂及凝血酶原片段F1+2
Acta Diabetol. 1996 Sep;33(3):241-5. doi: 10.1007/BF02048551.
4
Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects.糖尿病中的凝血激活:高血糖的作用及治疗前景
Diabetologia. 1993 Nov;36(11):1119-25. doi: 10.1007/BF00401055.
5
Aspirin and non-enzymatic glycation.
Acta Diabetol Lat. 1987 Apr-Jun;24(2):171-2. doi: 10.1007/BF02742856.
6
Increased alpha 2-macroglobulin in diabetes: a hyperglycemia related phenomenon associated with reduced antithrombin III activity.
Acta Diabetol Lat. 1989 Apr-Jun;26(2):147-54. doi: 10.1007/BF02581366.
7
Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans.
Diabetologia. 1990 Mar;33(3):163-7. doi: 10.1007/BF00404044.